awmsg logo



etravirine (Intelence®)


Reference No. 140

Publication date:
15/09/2009


Appraisal information

etravirine (Intelence®) 100 mg tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 15/07/2009
AWMSG meeting date: 12/08/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0609
Ministerial ratification: 11/09/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Etravirine (Intelence®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products. Treatment should be initiated by a specialist in accordance with BHIVA guidelines. Etravirine (Intelence®) is not recommended for use as first line therapy. AWMSG is of the opinion that etravirine (Intelence®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download